Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | F12 | P00748 | 4/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30268332 | 1.00 | KDM1A (0.41) | KDM1AF12BCHEHTR2AMEN1 | |
| Hydrochloric Acid SCHEMBL27979019 | 0.98 | KDM1A (0.40) | KDM1AF12BCHEHTR2AMEN1 | |
| Alcohol SCHEMBL27799209 | 0.89 | BCHE (0.39) | F12BCHESLC6A2SLC6A3SLC6A4 | |
| SCHEMBL14302642 | 0.88 | KDM1A (0.39) | KDM1AF12BCHEHTR2AMEN1 | |
| SCHEMBL25991428 | 0.82 | HTR2C (0.35) | KDM1AF12BCHESLC6A2SLC6A3 | |
| SCHEMBL129351 | 0.78 | HTR2A (0.37) | KDM1AHTR2AMEN1GAAKMT2A | |
| SCHEMBL12837114 | 0.75 | BCHE (0.35) | KDM1AF12BCHEMEN1ALDH1A1 | |
| SCHEMBL224810 | 0.75 | F12 (0.36) | KDM1AF12BCHEMEN1ALDH1A1 | |
| SCHEMBL20870878 | 0.75 | BCHE (0.35) | KDM1AF12BCHEMEN1ALDH1A1 | |
| SCHEMBL4433763 | 0.75 | HTR2C (0.39) | F12BCHEHTR2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419529-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240277673-A1 | METHODS OF TREATING BEHAVIOR ALTERATIONS | ORYZON GENOMICS SA (ES) | 2024-08-22 | — | — | US | disclosed |
| US-20230210834-A1 | RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2023-07-06 | — | — | US | disclosed |
| WO-2023069959-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-110066244-B | Method for synthesizing chiral tetrahydroquinoline by using saturated aldehyde | 上海泰坦科技股份有限公司 | 2022-06-28 | — | — | CN | disclosed |
| EP-3180314-B1 | PROCESS FOR PREPARING SYNTHETIC INTERMEDIATES FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | NEWAMSTERDAM PHARMA B V (NL) | 2022-06-22 | — | — | EP | disclosed |
| CN-114502540-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021039824-A1 | RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR | 国立大学法人 岡山大学 | 2021-03-04 | — | — | WO | disclosed |
| WO-2020243423-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| EP-2804859-B1 | NOVEL FAP INHIBITORS | UNIV ANTWERPEN (BE) | 2019-06-12 | — | — | EP | disclosed |
| EP-1100519-A1 | MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS | Advanced Medicine, Inc. (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1100802-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M Innovative Properties Company (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6110929-A | IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| WO-2000006577-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0977989-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999064041-A1 | MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| CN-1115761-A | Derivative, preparation and medical application of quinoline and imidazole | SYNTHELABO (FR) | 1996-01-31 | — | — | CN | disclosed |
| CN-1109471-A | Derivative of imidazol-4yl-piperidine, preparation of same and application of same in treatment | SYNTHELABO (FR) | 1995-10-04 | — | — | CN | disclosed |
| EP-0275520-B1 | SUBSTITUTED 1,8-NAPHTHYRIDINE DERIVATIVES AND FUNGICIDES CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1991-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210834-A1 | RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR | EMG1, TRDMT1, BCDIN3D | KDM1A 596/4885F12 4753/4885BCHE 3327/4885 |
| US-20240277673-A1 | METHODS OF TREATING BEHAVIOR ALTERATIONS | DOT1L, KDM1A, KDM1B | KDM1A 2/4885F12 3971/4885BCHE 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.